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Abstract
Background: There is no clear consensus on the better therapy [radiofrequency ablation (RFA) versus hepatic 
resection (HR)] for small hepatocellular carcinoma (HCC) eligible for surgical treatments. This study is a meta-analysis of 
the available evidence.
Methods: Systematic review and meta-analysis of trials comparing RFA with HR for small HCC published from 1997 to 
2009 in PubMed and Medline. Pooled odds ratios (OR) with 95% confidence intervals (95% CI) were calculated using 
either the fixed effects model or random effects model.
Results: One randomized controlled trial, and 9 nonrandomized controlled trials studies were included in this analysis. 
These studies included a total of 1411 patients: 744 treated with RFA and 667 treated with HR. The overall survival was 
significantly higher in patients treated with HR than in those treated with RFA at 3 years (OR: 0.56, 95% CI: 0.44-0.71), and 
at 5 year (OR: 0.60, 95% CI: 0.36-1.01). RFA has a higher rates of local intrahepatic recurrence compared to HR (OR: 4.50, 
95% CI: 2.45-8.27). In the HR group the 1, 3, and 5 years disease -free survival rates were significantly better than in the 
HR-treated patients (respectively: OR: 0.54, 95% CI: 0.35-0.84; OR: 0.44, 95% CI: 0.28-0.68; OR: 0.64, 95% CI: 0.42-0.99). The 
postoperative morbidity was higher with HR (OR: 0.29, 95% CI: 0.13-0.65), but no significant differences were found 
concerning mortality. For tumors ≤ 3 cm HR did not differ significantly from RFA for survival, as reported in three NRCTs .
Conclusions: HR was superior to RFA in the treatment of patients with small HCC eligible for surgical treatments, 
particularly for tumors > 3 cm. However, the findings have to be carefully interpreted due to the lower level of 
evidence.
Background
Hepatocellular carcinoma (HCC) is the fifth most com-
mon cancers in the world, with an estimated 500,000
deaths per year [1]. Advances in diagnostic imaging and
widespread application of screening programs in high-
risk populations have allowed detection of small HCC,
which can be curable by partial hepatic resection (HR),
liver transplantation, or local ablation therapies. Out of
these, liver transplantation, which offers the potential to
both resect the entire potentially tumor-bearing liver and
eliminate the cirrhosis, achieves the best results but can
be offered only to a minority of patients because of the
shortage of donors and high cost [2]. Therefore, HR has
generally been accepted as the first treatment of choice
for HCC in many centers. Nevertheless, the associated
cirrhosis limits the extent of surgery and thus increases
the risk of postoperative liver failure. So, many nonsurgi-
cal ablative methods have been developed, such as
cryoablation [3], percutaneous ethanol injection (PEI)
[4], acetic acid injection [5], radiofrequency ablation
(RFA) [6], microwave coagulation [7], and transcatheter
arterial chemoembolization (TACE) [8].
Among these therapies, RFA is a promising and
recently developed ablation technique. It induces deep
thermal injury in hepatic tissue while sparing the normal
parenchyma. Its basic principle includes generation of
high-frequency alternating current which causes ionic
agitation and conversion to heat, with subsequent evapo-
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ration of intracellular water which leads to irreversible
cellular changes, including intracellular protein denatur-
ation, melting of membrane lipid bilayers, and coagula-
tive necrosis of individual tumor cells. RFA was
recommended as the best treatment option for patients
with early stage HCC who are not suitable for resection
or transplantation in addition to PEI in the 2005 practice
guidelines issued by the American Association for the
Study of Liver Diseases [9]. Recently, a meta-analysis of
randomized controlled trial (RCT) showed that RFA
ablation is superior to PEI in the treatment of patients
with relatively preserved liver function and early-stage
non-surgical HCC with respect to survival and local con-
trol of the disease [10]. In contrast, whether RFA or HR is
the better treatment for HCC eligible for surgical treat-
ments has long been debated. Several RCT and non-ran-
domized controlled trial (NRCT) have been published in
an attempt to answer the above question. What follows is
a meta-analysis of these studies.
Methods
Study selection
Electronic searches were performed of the PubMed and
Medline from January 1997 to November 2009. The fol-
lowing Mesh search headings were used: "radiofrequency
ablation," "hepatocellular carcinoma". Reference lists of
all retrieved articles were manual searched for additional
studies. No language restrictions were made.
Data extraction
Two reviewers (BL and DX, respectively) independently
extracted the following parameters from each study: 1)
first author and year of publication; 2) number of
patients, patients characteristics, study design; and lastly,
3) treatment outcome. All relevant text, tables and figures
were reviewed for data extraction. Discrepancies between
the two reviewers were resolved by discussion and con-
sensus.
Criteria for inclusion and exclusion
For inclusion in the meta-analysis, a study had to fulfil the
following criteria: 1) compare the initial therapy effects of
RFA and HR for the treatment of small HCC, regardless
of the etiology of liver disease, cirrhotics status, or differ-
ences in viral hepatitis; 2) report on at least one of the
outcome measures mentioned below; 3) clearly docu-
ment indications for RFA and HR; 4) In dual (or multiple)
studies were reported by the same institution and/or
authors, either the one of higher quality or the most
recent publication was included in the analysis. The pri-
mary endpoints were overall survival at 1, 3, and 5 years,
and local recurrence. The secondary endpoints were dis-
ease-free survival at 1, 3, and 5 years, morbidity, and mor-
tality.
Small HCC are defined according to the criteria devel-
oped by Yao et al. [11] from the University of California,
San Francisco, a single HCC nodule of up to 6.5 cm, or
with up to 3 lesions, the largest of which is no larger than
4.5 cm.
Abstracts, letters, editorials and expert opinions,
reviews without original data, case reports and studies
lacking control groups were excluded. The following
studies were also excluded: 1) those dealing with unresec-
table HCC or HCC recurrence after hepatectomy; 2)
those with no clearly reported outcomes of interest; 3)
those evaluating patients with cholangiocellular carcino-
mas or liver metastases.
Statistical methods
The meta-analysis was performed using the Review Man-
ager (RevMan) software, version 4.2.7. All analyses were
performed on dichotomous outcomes. Pooled odds ratios
(OR) with 95% confidence intervals (95% CI) were calcu-
lated using either the fixed effects model or random
effects model. Heterogeneity was evaluated by χ2 and I2.
I2 < 25% and I2 > 50% reflect small and large inconsis-
tency, respectively. P < 0.05 was considered significant.
Results
Selection of trials
After initial screening, 19 potentially relevant clinical tri-
als of HCC were identified. Of these, three trials did not
separately analyze the results of RFA from the other local
therapies [12-14], two trials including patients with unre-
sectable HCC [15,16], one trial comparing resection with
RFA combined with preceding TACE [17], all 6 studies
were excluded. Three trials were also excluded from the
analysis, as no information concerning 3 or 5-year overall
survival was provided in these trials [18-20]. Finally, a
total of 10 studies (1 RCT and 9 NRCTs) [21-30] pub-
lished between 2004 and 2009 matched the selection cri-
teria and were therefore included. Eight of these studies
used percutaneous RFA [21-28], and the remaining 2
studies used laparoscopic RFA [29,30]. These studies
included a total of 1411 patients: 744 treated with RAF
and 667 treated with HR. The mean age ranged from 49.2
± 9.9 to 69.4 ± 9.1 years. Male: female ratio in the pooled
data was 2.4: 1. 84.7% of patients were in Child-Pugh class
A. Most patients (91.0%, 1139/1251) had a single tumor.
The median/mean tumor size (cm) ranged from 1.98 to
3.65. Median/mean duration of follow-up ranged from
21.9 to 43 months (Table 1).
Overall survival
There was no significant difference in overall survival
between the two groups at 1 year (all trials reported this
data, OR: 0.84, 95% CI: 0.58-1.21), and at 2 years (four tri-
als reported this data, OR: 0.80, 95% CI: 0.50-1.27),Z
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Table 1: Characteristics of included trials
Author/(year) Design Inclusion criteria Treatment No. of 
patients
M/F Mean age 
(years)
Mean tumor 
size(cm)
Mean AFP 
(ng/ml)
Child-Pugh A/B Mean follow-up 
(months)
Vivarelli NRCT (1)cirrhosis; (2)Child-Pugh class A or B RFA 79 67/12 67.8 ± 8.7 -- > 20 (n = 26) 43/36 15.6 ± 11.7
(2004) HR 79 57/22 65.2 ± 8.2 -- > 20 (n = 43) 70/9 28.9 ± 17.9
Hong NRCT (1) patients with liver cirrhosis whose Child-Pugh score 
is 5 or those without cirrhosis; (2)solitary tumor < 4 cm; 
(3) no vascular invasion; (4) no previous treatment
RFA 55 41/14 59.1 ± 9.6 2.4 ± 0.6 447.3 ± 981.3 55/0 22.7*
(2005) HR 93 69/24 49.2 ± 9.9 2.5 ± 0.8 644.0 ± 1745.6 93/0 25.5
Cho NRCT (1)Single or multiple (≤ 3 nodules) ≤ 5 cm; (2) Pugh-
Child Class A; (3) no extrahepatic metastasis
RFA 99 76/23 58 3.1 ± 0.8 -- 99/0 23 ± 9.4
(2005) HR 61 48/13 57 3.4 ± 1 -- 61/0 21.9 ± 9 .8
Montorsi NRCT (1) Cirrhosis (2)Solitary tumor ≤ 5 cm. single lesion; (3) 
Child A-B class; (4) segmental or subsegmental 
resection possible; (5) no previous treatment
RFA 58 43/15 67 ± 6 -- 377.7 ± 1051.8 40/18 25.7 ± 16.7
(2005) HR 40 33/7 67 ± 9 -- 361.3 ± 1026.2 32/8 22.4 ± 17.5
Chen RCT (1) age 18 to 75 years; (2) solitary tumor ≤ 5 cm; (3)no 
extrahepatic metastasis; (4) Pugh-Child Class A, with 
no history of ncephalopathy, ascites refractory to 
diuretics, or variceal bleeding; (5) ICG-R15 < 30%; (6) no 
previous treatment
RFA 71 56/15 51.9 ± 11.2 -- > 200 (n = 31) 71/0 27.9 ± 10.6
(2006) HR 90 75/15 49.4 ± 10.9 -- > 200 (n = 30) 90/0 29.2 ± 11.9
Lupo NRCT (1)Single tumor 3-5 cm; (2) no previous treatment; (3) 
no extrahepatic metastasis; (4) Child-Pugh class A or B
RFA 60 47/13 68 3.65* > 200 (n = 3) 44/16 27 ± 18.7
(2007) HR 42 33/9 67 4 > 200 (n = 5) 28/14 31.3 ± 24.3
Guglielmi NRCT (1)Cirrhosis; (2)Single or multiple (≤ 3 nodules) ≤ 6 cm; 
(3)Child-Pugh class A or B
RFA 109 88/21 -- -- > 200 (n = 43) 64/45 23
(2008) HR 91 73/18 -- -- > 200 (n = 34) 69/22 32
Hiraoka NRCT (1)Single tumor ≤ 3 cm; RFA 105 76/29 69.4 ± 9.1 1.98 114.5 79/26 847$
(2008) (2) Child-Pugh class A or B HR 59 44/15 62.4 ± 10.6 2.27 427.8 54/5 927
Abu-Hila NRCT (1)Cirrhosis; RFA 34 27/7 65 3* -- 27/7 30*
(2008) (2)Single tumor 1-5 cm. HR 34 26/8 67 3.8 -- 25/9 43
Santambrogio NRCT (1)Single tumor < 5 cm; (2)Child-Pugh class A RFA 74 59/15 68 ± 7 2.66 9 74/0 38.2 ± 28.4
(2009) HR 78 55/23 68 ± 8 2.91 8 78/0 36.2 ± 23.5
RCT: randomised controlled trial. NRCT: non-randomized controlled trial. AFP: alpha-fetoprotein. RFA: radiofrequency ablation. HR: hepatic resection. M: male. F: female. *: median. $: Day.Zhou et al. BMC Gastroenterology 2010, 10:78
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whereas the difference was significant and favourable to
HR group at 3 years (nine trials reported this data, OR:
0.56, 95% CI: 0.44-0.71) ( Figure 1), and at 5 year (five tri-
als reported this data, OR: 0.60, 95% CI: 0.36-1.01) (Table
2).
Intrahepatic recurrence
The pooled analysis of the 5 studies furnishing data
showed that RFA has a higher rates of local intrahepatic
recurrence compared to HR (OR: 4.50, 95% CI: 2.45-8.27)
(Figure 2). No differences were found between the two
groups with respect to the distant intrahepatic recurrence
(Table 2).
Disease-free survival
As Table 2 shows, our results indicate that 1, 3 and 5 year
disease-free survival rates were significantly higher in the
HR group.
Figure 1 Results of the meta-analysis on overall survival at 3 years.
Table 2: Summary of the results on the efficacy and safety of RFA versus HR in the management of small HCC
Variables No. of studies Results OR (95% CI) P-value I2
furnishing data RFA HR
Efficacy:
Overall survival
1 year 1021-30 89.7% 91.3% 0.84 (0.58, 1.21) 0.34 0%
2 years 423-25, 29 79.3% 82.2% 0.80 (0.50, 1.27) 0.35 0%
3 years 921-28, 30 63.5% 74.4% 0.56 (0.44, 0.71) < 0.001 46.3%
5 years 526-30 41.3% 51.9% 0.60 (0.36, 1.01) 0.05 61.6%
Intrahepatic recurrence
Local recurrence 522-24, 29, 30 19.0% 4.2% 4.50 (2.45, 8.27) < 0.001 10.7%
Distant recurrence 522-24, 29, 30 39.6% 38.8% 1.16 (0.83, 1.61) 0.38 27.1%
Disease-free survival
1 year 921-29 68.8% 80.3% 0.54 (0.35, 0.84) 0.006 59.2%
2 years 324, 25, 29 49.6% 74.3% 0.34 (0.21, 0.55) < 0.001 0%
3 years 821-28 34.9% 54.4% 0.44 (0.28, 0.68) < 0.001 66.7%
5 years 425-28 18.4% 23.8% 0.64 (0.42, 0.99) 0.05 47.2%
Safety:
Morbidity 623, 25, 26, 27, 29, 30 9.6% 32.5% 0.29 (0.13, 0.65) 0.003 72.7%
Mortality 1021-30 0.1% 0.8% 0.36 (0.10, 1.27) 0.11 0%
RFA: radiofrequency ablation.HR: hepatic resection. OR: odds ratios.Zhou et al. BMC Gastroenterology 2010, 10:78
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Safety
The rate of postoperative morbidity was significantly
higher in patients treated with HR than in those treated
with RFA (six trials reported this data, OR: 0.29, 95% CI:
0.13-0.65), but no differences were found between the
two groups with respect to postoperative mortality (all
trials reported this data, OR: 0.36, 95% CI: 0.10-1.27).
There were 1 death reported in the RFA group, and 6 in
the HR group, giving a mean mortality rate of 0.1 per cent
and 0.8 per cent, respectively (Table 2).
Comparison between the two groups in HCCs ≤ 3 cm
Three NRCTs compared RFA versus HR for patients with
tumors ≤ 3 cm. Of these, two studies included only
patients with single tumor [27,28]. There was no signifi-
cant difference in overall and disease -free survival
between the groups at 1, 3, and 5 years in each included
study (Table 3). In the further analysis, survival of
patients with single or multiple tumors was similar in the
two treatment groups, as reported by Vivarelli et al. [21].
Thus, we did not perform a meta-analysis of these stud-
ies.
Discussion
Meta-analysis, a quantitative technique for therapeutic
evaluation, may be used when controversy persists after
several trials. Although meta-analysis has traditionally
been applied and is best confined to RCT, meta-analytical
techniques using NRCT might be a valid method in some
clinical settings in which either the number or the sample
size of RCT is insufficient [31].
This meta-analysis shows that in patients with small
HCC the treatment with HR is superior to treatment with
RFA. HR had a significant better survival in terms of
overall survival at 3, and 5 years, and disease-free survival
at 1, 3, and 5 years. The difference at 5 years overall sur-
vival was marginally significant due to the number of
studies furnishing combinable data on this outcome is
limited. Although the only RCT shows nearly equivalent
survival with the two treatments, however, in this study
19 of 90 patients (21%) who were randomized for RFA
converted to HR [25].
High rate of intrhepatic recurrence after ablation thera-
pies and/or surgical resection is the main cause of late
death of patients with HCC. In current study, local recur-
rence was found to be more frequent after RFA than after
HR. Local recurrences after RFA may be attributable to
insufficient ablation of the primary tumor and/or the
presence of tumor venous invasion in the adjacent liver.
Surgical resection could remove the primary tumor and
venous tumor thrombi [12]. This may explain the better
outcomes following HR.
Figure 2 Results of the meta-analysis on local recurrence rate.
Table 3: Studies comparing RFA versus HR for HCC ≤ 3 cm
Author Treatment No. of 
patients
Survival (%) Disease-free survival (%) P-value
1-year 3-year 5-year 1-year 3-year 5-year
V i v a r e l l i R F A 2 2 8 9- - 5 07 03 4- - N S
HR 21 89 -- 79 84 67 --
Guglielmi RFA 32 91 50 29 72 36 36 NS
HR 31 89 78 54 80 58 19
Hiraoka RFA 105 95.1 87.8 59.3 87.5 58.7 24.6 NS
HR 59 98.1 91.4 59.4 91.4 64.3 22.4
RFA: radiofrequency ablation.HR: hepatic resection. NS: not significantZhou et al. BMC Gastroenterology 2010, 10:78
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As regards the distant recurrence, no differences were
found between the two groups. This fnding is reasonable
because the occurrence of distant recurrence is corre-
lated with the host factors and initial tumor factors [32],
and the treatment does not affect this outcome.
Although the overall rate of postoperative morbidity
was 32.5% in patients treated with HR, which is signifi-
cantly higher than in those treated with RFA. However,
these rates do not translate into an increase in mortality.
The results of this meta-analysis should be interpreted
with caution for several reasons. First, the majority of
data in the present study comes from NRCTs, and the
overall level of clinical evidence is low. Second, there are
important heterogeneity between two groups. This could
be due to a bias in patient selection in several series in
terms of patient demographics and tumor characteristics.
Patients undergoing RFA had a few less favourable char-
acteristics such as old age, multiple nodules, severe
chronic liver disease, high serum level of alpha-fetopro-
tein and aspartate aminotransferase level [22,25,27,28].
However, Guglielmi et al. [27] found that these biases did
not influence the statistical analysis in the subgroups and
in the multivariate analyses. We applied a random effect
model to take between study variation into consideration.
This does not necessarily rule out the effect of heteroge-
neity between studies, but one may expect a very limited
influence.
Third, RFA can be performed by percutaneous, laparo-
scopic or open approaches. Laparoscopic and open
approaches increase the chance of detection of unknown
intrahepatic and extrahepatic tumors because they allow
complete abdominal exploration and intraoperative ultra-
sound assessment. The additional advantages of open and
laparoscopic approaches are the accurate placement of
electrodes and the possible treatment of tumors in percu-
taneously inaccessible areas of the liver and tumors in
close proximity to or invading the adjacent organs [6]. On
the other hand, several different RFA systems were used
in the treatment centers, such as RIT A Medical System
(Mountain View, CA), Radionics (Burlington, MA) and
Valleylab (Boulder, CO). Different approaches and RFA
systems would also impact on the pooling of data and
interpretation of results. Unfortunately, we failed to find
any study that compared the outcomes of different
approaches and RFA systems on therapy efficacy of HCC.
Thus, we were not able to assess the influence of these
factors.
Vascular invasion is a well-established prognostic indi-
cator of HCC. Considering that vascular invasion was less
frequent in tumors ≤ 3 cm [33], this may explain equiva-
lent survival outcome between two groups, as reported in
3 trials. RFA appears to be an effective alternative treat-
ments modality for HCC ≤ 3 cm. However, the only three
studies containing 270 patients make the interpretation
of these results insufficient. Recently, in a large, prospec-
tive study from the Liver Cancer Study Group of Japan,
7185 patients with no more than 3 tumors (≤ 3 cm) were
classified into either a resection (n = 2857), RFA (n =
3022), or PEI group (n = 1306). The comparison of all
three groups showed that surgical resection may be supe-
rior to ablation with respect to the prevention of recur-
rence [20]. Thus, the efficacy compared to HR or ablation
in the treatment for HCC ≤ 3 cm still is a matter of dis-
cussion and further studies are required to provide more
adequate data answer this question.
Conclusions
HR was superior to RFA in the treatment of patients with
small HCC eligible for surgical treatments, particularly
for tumors > 3 cm. However, the findings have to be care-
fully interpreted due to the lower level of evidence. Fur-
ther RCT are needed to define the exact value of HR and
RFA for small HCC, even for tumors ≤ 3 cm.
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